6397 RESULTS
Sort By:
Ionis announced top-line results of a Phase 3 trial of their drug for familial amyloid neuropathy. It met both primary endpoints but caused serious side effects in some people.
By targeting distinct cell populations in the external globus pallidus, researchers restore mobility to a mouse model of Parkinson’s disease.
Tyrosine kinase inhibitors kept diseased motor neurons alive in vitro, and notched positive findings in a recent Phase 3 trial. A new paradigm for ALS treatment?
Over the past 15 years, deaths attributable to Alzheimer’s have risen 55 percent, according to the CDC, and more people are living at home when they die, suggesting a need to support caregivers.
Protein Liquid-Liquid Phase Transitions: The Science Is About to Gel Confused about protein liquid-liquid phase transitions? You are not alone. Researchers working in this emerging field gathered in Leuven in early May to make sense of the latest data lin
Immune cells lacking the receptor fail to respond to injury and aging, resulting in overall poor brain health in mouse models.
Injected α-synuclein fibrils triggered pathology throughout the mouse brain, even in regions not neuroanatomically connected to the injection site. Astrocytes were loaded with inclusions.
In a human cell model, VCP variants trigger a cascade of neuronal disruption and hobble astrocytes’ ability to support motoneurons.
CHCHD10 mutations target mitochondria and TDP-43, while a UBQLN4 allele hits the proteasome.
By accounting for harmless variants of known ALS genes, researchers made a downward correction of the genetic risk associated with sporadic cases.
Based on the tiny effect size seen in overall negative solanezumab trials in mild Alzheimer’s disease, researchers are going big in a secondary prevention trial.
Instead of clearing plaques, do microglia seed them? The brain’s immune cells continue to take researchers by surprise.
Microglial Regulation and Function Scrutinized at Heidelberg Meeting A New Explanation for Dendritic Tau: It’s Made There Alzheimer’s Proteomics Treasure Trove? sAPP Binds GABA Receptor, and More News on APP At Heidelberg meeting, scientists shared and de
23andMe sells people information about their Alzheimer’s and Parkinson’s risk. They include tricky-to-interpret raw data on dozens of disease genes. Should such direct-to-consumer testing companies offer better counselling and referral?
A new prize seeks the ideal mix of factors to forecast who will progress to Alzheimer’s symptoms.
